Advertisement

Pharmaceutical Medicine

, Volume 32, Issue 1, pp 21–30 | Cite as

Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children

  • Michael RiederEmail author
Review Article

Abstract

Drug therapy for children is one of the cornerstone developments that have sharply reduced childhood mortality. Despite this, many challenges remain in ensuring that children receive safe and effective drug therapy. There are unique issues in treating children with oral medication relating to development, existing formulations and medication acceptability. Medication acceptability in children is complex relating to a wide range of factors, including drug palatability. Over the past decade there has been an increasing interest in and research as to how to improve and enhance child-specific drug formulations including the development of specific instruments for assessing drug palatability in children and new approaches to teaching medication literacy to families. Approaches to enhancing drug acceptability have also included organoleptic (taste masking) strategies as well as the creation of a number of innovative taste-blocking strategies and new technologies for formulation preparation. Polymer coating, microencapsulation and heat melt technologies have resulted in drug formulations that are now being assessed in children while soft melt and gel formulations are now commonly used. Mini-tablets offer the potential of using solid delivery systems in even very young infants. This work has resulted in a number of highly promising developments that are being evaluated for clinical use as well as providing insights into new directions in pursuit of the common goal of effective and safe drug therapy for children. On-going challenges include the need for drug regulatory agencies to work closely with drug regulatory agencies in facilitating innovation in formulation design and approval.

Notes

Compliance with Ethical Standards

This work was supported by the CIHR-GSK Chair in Paediatric Clinical Pharmacology at the University of Western Ontario. Dr. Rieder has served as a consultant to Health Canada, the National Institutes of Health and the Medical Research Council.

References

  1. 1.
    Weinshilboum R. The therapeutic revolution. Clin Pharmacol Ther. 1987;42:481–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Rieder MJ. If children ruled the pharmaceutical industry: the need for pediatric formulations. Drug News Perspect. 2010;23:458–64.PubMedGoogle Scholar
  3. 3.
    Rieder MJ, Matsui DM, MacLeod S. Myths and challenges—drug utilization for Canadian children. Paediatr Child Health. 2003;8(Supple A):7A–8A.Google Scholar
  4. 4.
    Chai G, Governale L, McMahon AW, et al. Trends of outpatient prescription drug use in US children, 2002–2010. Pediatrics. 2012;130:23–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.CrossRefPubMedGoogle Scholar
  6. 6.
    Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. Pediatr Pharmacol Ther. 2014;19:262–76.Google Scholar
  7. 7.
    Brouwer K, Aleksunes LM, Brandys B, Pediatric Transporter Working Group, et al. Human ontogeny of drug transporters: review and recommendations of the Pediatric Transporter Working Group. Clin Pharmacol Ther. 2015;98:266–87.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rieder MJ. Novel approaches to adverse drug reactions in children. Pediatr Clin N Am. 2012;59:1001–4.CrossRefGoogle Scholar
  9. 9.
    Kauffman RE. Status of drug approval processes and regulation of medications for children. Curr Opin Pediatr. 1995;7(2):195–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Shirkey HC. Editorial comment: therapeutic orphans. J Pediatr. 1968;72:119–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Bleicher EW. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context. Food Drug Law J. 2009;64(3):531–64.PubMedGoogle Scholar
  12. 12.
    Waisel DB. Moral responsibility to attain thorough pediatric drug labeling. Paediatr Anaesth. 2009;19:989–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Hawcutt DB, Smyth RL. Drug development for children: how is pharma tackling an unmet need? IDrugs. 2008;11(7):502–7.PubMedGoogle Scholar
  14. 14.
    Rodriguez W, Selen A, Avant D, et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics. 2008;121(3):530–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Lau C. Development of suck and swallow mechanisms in infants. Ann Nutr Metab. 2015;66(suppl 5):7–14.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    LaMantia AS, Moody SA, Maynard TM, et al. Hard to swallow: developmental biological insights into pediatric dysphagia. Dev Biol. 2016;409(2):329–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Delaney AL, Arvedson JC. Develop disabilities. Res Rev. 2008;2008(14):105–17.Google Scholar
  18. 18.
    Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr (Phila). 2006;45:725–33.CrossRefGoogle Scholar
  19. 19.
    Chandrashekar J, Hoon MA, Ryba NJ, Zuker CS. The receptors and cells for mammalian taste. Nature. 2006;444:288–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Chaudhari N, Roper SD. The cell biology of taste. J Cell Biol. 2010;190:285–96.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008;30:2120–32.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gaynes BJ, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use. Drug Saf. 2002;25:233–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Chiu HY, Tsai TF. Topical use of systemic drugs in dermatology: a comprehensive review. J Am Acad Dermatol. 2011;65:e1–22.CrossRefGoogle Scholar
  24. 24.
    Sears MR, Taylor DR, Lake DC, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336:3191–6.CrossRefGoogle Scholar
  25. 25.
    Baguley D, Lim E, Bevan A, Pallet A, Faust SN. Prescribing for children—taste and palatability affect adherence to antibiotics: a review. Arch Dis Child. 2012;97:293–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. Int J Pharm. 2014;469:245–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Zajicek A, Fossler MJ, Barrett JS, et al. A Report from the Pediatric Formulations Task Force: perspectives on the state of child-friendly oral dosage forms. AAPS Pharm Sci Tech. 2013;15:1072–81.Google Scholar
  28. 28.
    Sunakawa K, Akita H, Iwata S, et al. Rational use of oral antibiotics for pediatric infections. Infection. 1995;23(Suppl 2):S74–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Al-Shammari SA, Khoja T, Al-Yamani MJ. Compliance with short-term antibiotic therapy among patients attending primary health centres in Riyadh, Saudi Arabia. J R Soc Health. 1995;115:231–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Lin D, Seabrook J, Matsui D, et al. Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada. Pharmacoepidemiol Drug Saf. 2011;20(12):1246–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Rieder M. How sweet it isn’t: a new formulation of sodium phenylbutyrate and the challenge of palatability for medicines in children. Arch Dis Child. 2012;97:1080.CrossRefPubMedGoogle Scholar
  32. 32.
    Wax PM. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med. 1995;122:456–61.CrossRefPubMedGoogle Scholar
  33. 33.
    Jamesa C, Lainga DG, Orama NA. Comparison of the ability of 8–9-year-old children and adults to detect taste stimuli. Physiol Behav. 1997;62:193–7.CrossRefGoogle Scholar
  34. 34.
    Gie Liem D, de Graaf C. Sweet and sour preferences in young children and adults; role of repeated exposures. Physiol Behav. 2004;83:421–9.CrossRefGoogle Scholar
  35. 35.
    Guffon G, Kibleur Y, Copula W, Tissen W, Breitkreutz J. Developing a new formulation of sodium phenylbutyrate. Arch Dis Child. 2012;97:1081–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Matsui D, Barron A, Rieder MJ. Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers. Ann Pharmacother. 1996;30:586–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Matsui D, Lim R, Tschen T, Rieder MJ. Assessment of the palatability of β-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med. 1997;151:599–602.CrossRefPubMedGoogle Scholar
  38. 38.
    Angelilli ML, Toscani M, Matsui DM, Rieder MJ. Palatability of oral antibiotics among children in an urban primary care center. Arch Pediatr Adolesc Med. 2000;154:267–70.CrossRefPubMedGoogle Scholar
  39. 39.
    Dagnone D, Matsui DM, Rieder MJ. Assessment of the palatability of vehicles for activated charcoal in paediatric volunteers. Pediatr Emerg Care. 2002;18:19–21.CrossRefPubMedGoogle Scholar
  40. 40.
    Hames H, Seabrook J, Matsui D, Rieder MJ, Joubert G. Palatability study of a flavored dexamethasone preparation versus prednisolone liquid in children with asthma exacerbation in a Pediatric Emergency Department. Can J Clin Pharmacol. 2008;15:e95–8.PubMedGoogle Scholar
  41. 41.
    Goldberg SL, Giardina PJ, Chirnomas D, et al. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60:1507–12.CrossRefPubMedGoogle Scholar
  42. 42.
    Bastiaans DT, Immohr LI, Zeinstra GG, et al. In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir. Br J Clin Pharmacol. 2017;83:2789–97.Google Scholar
  43. 43.
    Kodish E. Ethics and research with children: a case-based approach. New York: Oxford University Press; 2005.Google Scholar
  44. 44.
    Sammons HM, Malhotra J, Choonara I, et al. British and Canadian views on the ethics of paediatric clinical trials. Eur J Clin Pharmacol. 2007;63:431–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Dove ES, Avard D, Black L, Knoppers BM. Emerging issues in paediatric health research consent forms in Canada: working towards best practices. BMC Med Ethics. 2013;14:5.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Rieder MJ. (Member, Expert Panel): improving medicines for children in Canada. Council of Canadian Academies; 2014.Google Scholar
  47. 47.
    Davies EH, Tuleu C. Medicines for children: a matter of taste. J Pediatr. 2008;2008(153):599–604.CrossRefGoogle Scholar
  48. 48.
    Wizenburg G, Desset-Brethes S. Industry perspective on palatability testing in children—two case studies. Int J Pharm. 2012;435:131.CrossRefGoogle Scholar
  49. 49.
    Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Members of the BCS Task Force. Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. Clin Ther. 2012;34:S11–24.Google Scholar
  50. 50.
    Committee for Medicinal Products for Human Use, Paediatric Committee. Guideline on pharmaceutical development of medicines for paediatric use. European Medicines Agency, London, UK, 2013.Google Scholar
  51. 51.
    Tuleu C, Breitkreutz J. Education paper: formulation issues in pediatric clinical pharmacology. Eur J Pediatr. 2013;172:717–20.CrossRefPubMedGoogle Scholar
  52. 52.
    Batchelor H, Rayner O, Nickless J, et al. Children with cystic fibrosis: understanding issues related to oral administration of liquid flucloxacillin. Arch Dis Child. 2016;101:e2.CrossRefGoogle Scholar
  53. 53.
    Aljebab F, Alanazi M, Choonara I, Conroy S. Observational study on the palatability and tolerability of oral prednisolone and oral dexamethasone in children in Saudi Arabia and the UK. Arch Dis Child. 2017;102:1–6.CrossRefGoogle Scholar
  54. 54.
    Cohen R, de La Rocque F, Lecuyer A, et al. Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. Eur J Pediatr. 2009;168:851–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Anand V, Kataria M, Kukkar V, Saharan V, Choudhury PK. The latest trends in the taste assessment of pharmaceuticals. Drug Discov Today. 2007;12:257–65.CrossRefPubMedGoogle Scholar
  56. 56.
    Bai S, Dormer N, Shoults C, Meyer A, Carol D, Pierce CD, Neville KA, Kearns GL. Palatability of a novel oral formulation of prednisone in healthy young adults. J Pharm Pharmacol. 2017;69:489–96.CrossRefPubMedGoogle Scholar
  57. 57.
    Ali AA, Charoo NA, Abdallah DB. Pediatric drug development: formulation considerations. Drug Dev Ind Pharm. 2014;40:1283–99.CrossRefPubMedGoogle Scholar
  58. 58.
    Mistry P, Batchelor H. Evidence of acceptability of oral paediatric medicines: a review. J Pharm Pharmacol. 2017;69:361–76.CrossRefPubMedGoogle Scholar
  59. 59.
    Allen LV Jr. Dosage form design and development. Clin Ther. 2008;30:2102–11.CrossRefPubMedGoogle Scholar
  60. 60.
    Klovrova S, Zahalka L, Matysova L, Horak P, Sklubalova Z. Pediatric oral solutions with propranolol hydrochloride for extemporaneous compounding: the formulation and stability study. Ceska Slov Fam. 2013;62:35–9.Google Scholar
  61. 61.
    Ferrarini A, Biachetti AA, Fossali EF, et al. What can we do to make antihypertensive medications taste better for children? Int J Pharm. 2013;457:333–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Sohi H, Sultana Y, Khar RK. Taste-masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm. 2004;30:429–48.CrossRefPubMedGoogle Scholar
  63. 63.
    Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical taste-masking technologies: a patent review. Recent Pat Drug Del Formul. 2009;3:26–39.CrossRefGoogle Scholar
  64. 64.
    Ranmal SR, Cram A, Tuleu C. Age-appropriate and acceptable paediatric dosage forms: insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study. Int J Pharm. 2016;514:296–307.CrossRefPubMedGoogle Scholar
  65. 65.
    Vaillancourt R, Truong Y, Karmali S, et al. Instructions for masking the taste of medication for children: validation of a pictogram tool. Can Pharm J (Ott). 2016;150:52–9.CrossRefGoogle Scholar
  66. 66.
    Al-kasemi B, Alsirawan B, Bashiman M, El-Zein H. Mechanical microencapsulation: the best technique in taste masking for the manufacturing scale—effect of polymer encapsulation on drug targeting. J Control Release. 2017;260:134–41.CrossRefGoogle Scholar
  67. 67.
    Münster M, Schoch C, Schmidt C, Breitkreutz J. Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel. Eur J Pharm Sci. 2017;109:446–54.CrossRefPubMedGoogle Scholar
  68. 68.
    Pein M, Preis M, Eckert C, Kleine FE. Taste-masking assessment of solid oral dosage forms—a critical review. Int J Pharm. 2014;465:239–54.CrossRefPubMedGoogle Scholar
  69. 69.
    Walsh J, Cram A, Woertz K, Breitkreutz J, Winzenburg G, Turner R, Tuleu C. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients. Adv Drug Deliv Rev. 2014;73:14–33.CrossRefPubMedGoogle Scholar
  70. 70.
    Ibrahim K, Al Ansari K. Flavored intravenous ondansetron administered orally for the treatment of persistent vomiting in children. J Trop Pediatr. 2016;62:288–92.CrossRefPubMedGoogle Scholar
  71. 71.
    Batchelor H, Maukonen AM, Klein S, Davit B, Ju R, Ternik R, Heimbach T, Lin W, Wang J, Storey D. Food effects in paediatric medicines development for products Co-administered with food. Int J Pharm. 2017.  https://doi.org/10.1016/j.ijpharm.2017.05.011.
  72. 72.
    Neumann U, Whitaker MJ, Wiegand S, Krude H, Porter J, Davies M, Digweed D, Voeet B, Ross RJ, Blankensteing O. Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clin Endocrinol (Oxf). 2017.  https://doi.org/10.1111/cen.13447.Google Scholar
  73. 73.
    Preis M, Grother L, Axe P, Breitkreutz J. In-vitro and in-vivo evaluation of taste-masked cetirizine hydrochloride formulated in oral lyophilisates. Int J Pharm. 2015;491:8–16.CrossRefPubMedGoogle Scholar
  74. 74.
    Batchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: key considerations and current challenges. Adv Drug Deliv Rev. 2014;73:102–26.CrossRefPubMedGoogle Scholar
  75. 75.
    Klingmann V, Meissner T, Breitkreutz J, Moeltner A, Bosse HM. Acceptability of uncoated mini-tablets in neonates—a randomized controlled trial. J Pediatr. 2015;167:893–6.CrossRefPubMedGoogle Scholar
  76. 76.
    Kluk A, Sznitowska M, Brandt A, Sznurkowska K, et al. Can preschool-aged children swallow several minitablets at a time? Results from a clinical pilot study. Int J Pharm. 2015;485:1–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Peris M. Orally disintegrating films and mini-tablets—innovative dosage forms of choice for pediatric use. AAPS Pharm Sci Tech. 2015;16:234–41.CrossRefGoogle Scholar
  78. 78.
    Hattrem MN, Dille MJ, Seternes T, Ege T, Draget KI. The relative bioavailability of ibuprofen after administration with a novel soft chewable drug formulation. Clin Pharmacol Drug Dev. 2017;0:1–9.Google Scholar
  79. 79.
    Cutler AJ, Mattingly GW. Beyond the pill: new medication delivery options for ADHD. CNS Spectr. 2017;7:1–12.CrossRefGoogle Scholar
  80. 80.
    Salunke S, Liu F, Batchelor H, European Paediatric Formulation Initiative (EuPFI), et al. European paediatric formulation initiative (EuPFI)—formulating ideas for better medicine for children. AAPS Pharm Sci Tech. 2017;18:257–62.CrossRefGoogle Scholar
  81. 81.
    Ternik R, Liu F, Bartlett JA, Khong YM, Tan DCT, Dixit T et al. Assessment of swallowability and palatability of oral dosage forms in children: report from an M-CERSI pediatric formulation workshop. Int J Pharm. 2017.  https://doi.org/10.1016/j.ijpharm.2017.08.088.
  82. 82.
    Bahia MS, Nissim I, Niv MY. Bitterness prediction in-silico: a step towards better drugs. Int J Pharm. 2017.  https://doi.org/10.1016/j.ijpharm.2017.03.076.
  83. 83.
    Jaggupulli A, Howard R, Upadhyaya JD, Bhullar RP, Chelikani P. Bitter taste receptors: novel insights into the biochemistry and pharmacology. Int J Biochem Cell Biol. 2016;77:184–96.CrossRefGoogle Scholar
  84. 84.
    Gittings S, Turnbull N, Roberts CJ, Bershkovich P. Dissolution methodology for taste masked oral dosage forms. J Control Release. 2014;173:32–42.CrossRefPubMedGoogle Scholar
  85. 85.
    Pöllinger N. Microparticulates as drug carriers for pediatric use. Int J Pharm. 2013;457:337–58.CrossRefGoogle Scholar
  86. 86.
    Caffarel-Salvador E, Tuan-Mahmood TM, McElnay JC, et al. Potential of hydrogel-forming and dissolving microneedles for use in paediatric populations. Int J Pharm. 2015;489:158–69.CrossRefPubMedGoogle Scholar
  87. 87.
    Jagani M, Legay H, Ranmal SR, et al. Can a flavoured spray (Pill Glide) help children swallow their medicines? A pilot study. Pediatrics. 2016;136:e20160680.CrossRefGoogle Scholar
  88. 88.
    Nagtegaal MJ, Swen JJ, Hanff LM, Schimmel KJM, Guchelaar HJ. Pharmacogenomics of taste: turning bitter pills sweet? Pharmacogenomics. 2014;15:111–9.CrossRefPubMedGoogle Scholar
  89. 89.
    Allen AL, McGeary JE, Knopik VS, Hayes JE. Bitterness of the non-nutritive sweetener acesulfame potassium varies with polymorphisms in TAS2R9 and TAS2R31. Chem. Senses. 2013;38:379–89.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Rieder MJ, Carleton B. Pharmacogenomics and adverse drug reactions in children. Front Genet. 2014;5:1–10.CrossRefGoogle Scholar
  91. 91.
    Bryson S. Patient-centred, administration friendly medicines for children—an evaluation of children’s preferences and how they impact medication adherence. Int J Pharm. 2014;469:257–9.CrossRefPubMedGoogle Scholar
  92. 92.
    Liu F, Ranmal S, Batchelor HK, et al. Formulation factors affecting acceptability of oral medicines in children. Int J Pharm. 2015;492:341–3.CrossRefPubMedGoogle Scholar
  93. 93.
    Venables R, Batchelor H, Hodson J, Stirling H, Marriott J. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. Int J Pharm. 2015;480:55–62.CrossRefPubMedGoogle Scholar
  94. 94.
    Walsh J, Ranmal SR, Ernest TB, Liu F. Patient acceptability, safety and access: a balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int J Pharm. 2017.  https://doi.org/10.1016/j.ijpharm.2017.07.017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Paediatrics, London Health Sciences CentreChildren’s Hospital of Western OntarioLondonCanada

Personalised recommendations